Evidence map›Paper›PMID 36892360›Full record

ReviewDermatology practical & conceptual2023

Narrative Review of Drug-Associated Nail Toxicities in Oncologic Patients.

Anastasia Emvalomati, Valentina Oflidou, Chryssoula Papageorgiou, Christina Kemanetzi, Maria Giannouli, Evangelia Kalloniati, Konstantinos Efthymiadis, Chrysanthi Koukoutzeli, Eleni Timotheadou, Anastasia Trigoni and 4 more

Open access · diamondAbstract readReview
In one paragraph

Review in Dermatology practical & conceptual, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Anastasia EmvalomatiSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Valentina OflidouSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Chryssoula PapageorgiouSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Christina KemanetziSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Maria GiannouliSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Evangelia KalloniatiSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Konstantinos EfthymiadisDepartment of Medical Oncology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Chrysanthi KoukoutzeliDepartment of Medical Oncology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Eleni TimotheadouDepartment of Medical Oncology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Anastasia TrigoniSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Aikaterini PatsatsiSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Elizabeth LazaridouSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Zoe ApallaSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Myrto TrakatelliSecond Department of Dermatology, Aristotle University of Thessaloniki, "Papageorgiou" General Hospital, Thessaloniki, Greece.
Aristotle University of Thessaloniki · GRPapageorgiou General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNail toxicity represents one of the most common cutaneous adverse effects of both classic chemotherapeutic agents and new oncologic drugs, including targeted treatments and immunotherapy.

objectivesWe aimed to provide a comprehensive literature review of nail toxicities derived from conventional chemotherapeutic agents, targeted therapies (EGFR inhibitors, multikinase inhibitors, BRAF and MEK inhibitors) and immune checkpoint inhibitors (ICIs), including clinical presentation, implicated drugs and approaches for prevention and management.

methodsRetrieved literature from PubMed registry database was reviewed to include all articles published up to May 2021 relevant to the clinical presentation, diagnosis, incidence, prevention, and treatment of oncologic treatment-induced nail toxicity. The internet was searched for relevant studies.

resultsA wide spectrum of nail toxicities is associated with both, conventional and newer anticancer agents. The frequency of nail involvement, especially with immunotherapy and new targeted agents remains unknown and patients with different cancer types receiving different regimens may develop the same nail disorder, whereas patients with the same type of cancer under the same chemotherapeutic treatment may develop different types of nail alterations. The underlying mechanisms of the varying individual susceptibility and the diverse nail responses to various anticancer treatments need further investigation.

conclusionEarly recognition and treatment of nail toxicities can minimize their impact, allowing better adherence to conventional and newer oncologic treatments. Dermatologists, oncologists and other implicated physicians should be aware of these burdensome adverse effects in order to guide management and prevent impairment of patients' quality of life.

Identifiers

PMID36892360
PMCPMC9946059
OpenAlexW4318830714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.